NCT03560752View on ClinicalTrials.gov

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

January 22, 2022

Study Completion Date

August 27, 2025

Conditions
Accelerated Phase CML, BCR-ABL1 PositiveAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionChronic Lymphocytic LeukemiaChronic Phase CML, BCR-ABL1 PositiveCytomegalovirus PositiveDonorHematopoietic Cell Transplant RecipientHodgkin LymphomaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmNon-Hodgkin LymphomaMyelofibrosisHematopoietic and Lymphoid Cell Neoplasm
Interventions
BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given via injection

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER